Propanc Biopharma (Propanc Biopharma) Total Liabilities : $3.74 Mil (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Propanc Biopharma Total Liabilities?

Propanc Biopharma's Total Liabilities for the quarter that ended in Mar. 2024 was $3.74 Mil.

Propanc Biopharma's quarterly Total Liabilities increased from Sep. 2023 ($3.17 Mil) to Dec. 2023 ($3.81 Mil) but then declined from Dec. 2023 ($3.81 Mil) to Mar. 2024 ($3.74 Mil).

Propanc Biopharma's annual Total Liabilities increased from Jun. 2021 ($3.08 Mil) to Jun. 2022 ($3.11 Mil) and increased from Jun. 2022 ($3.11 Mil) to Jun. 2023 ($3.18 Mil).

Propanc Biopharma Total Liabilities Historical Data

The historical data trend for Propanc Biopharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Propanc Biopharma Total Liabilities Chart

Propanc Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

4.40

3.74

3.08

3.11

3.18

Propanc Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															3.09	3.18	3.17	3.81	3.74

Propanc Biopharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Propanc Biopharma's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3.158	+	(0.019	+	0.001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3.18

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	0.06	-	-3.117
	=	3.18

Propanc Biopharma's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3.688	+	(0.049	+	-6.9388939039072E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3.74

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	0.037	-	-3.7
	=	3.74

Propanc Biopharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Propanc Biopharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Propanc Biopharma (Propanc Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Propanc Biopharma Inc (OTCPK:PPCB) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124

Website

https://www.propanc.com

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Executives

Josef Zelinger	director	59 SEYMOUR ROAD, ELSTERNWICK C3 3185
Carlo M Campiciano	officer: CFO & Secretary	C/O. PROPANC BIOPHARMA,INC., 302, 6 BUTLER STREET, CAMBERWELL C3 3124
Julian Norman Kenyon	director	BEECHWOOD, EMBLEY LANE, EAST WELLOW, ROMSEY HAMPSHIRE X0 SO516DN
James Andrew Nathanielsz	director, officer: CEO, CFO, Secretary, Treasurer	1/76 SUMMERHILL ROAD, GLEN IRIS, VICTORIA C3 3146